» Articles » PMID: 17197028

Efficacy and Safety of Latanoprost Versus Travoprost in Exfoliative Glaucoma Patients

Overview
Journal Ophthalmology
Publisher Elsevier
Specialty Ophthalmology
Date 2007 Jan 2
PMID 17197028
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To evaluate 24-hour intraocular pressure (IOP) efficacy of latanoprost versus travoprost, each given every evening, in exfoliative glaucoma patients.

Design: Prospective, observer-masked, crossover comparison.

Participants: Forty patients with exfoliation glaucoma.

Methods: Patients with a pressure of >24 mmHg were randomized to latanoprost or travoprost for an 8-week treatment period after a 6-week medicine-free period. Patients were then switched to the opposite treatment for the second period. At untreated baseline and at the end of each treatment period the IOP was measured at 6 am, 10 am, 2 pm, 6 pm, 10 pm, and 2 am.

Main Outcome Measure: Diurnal IOP.

Results: The mean 24-hour IOP was 25.1+/-2.5 mmHg at baseline, 17.8+/-2.1 mmHg on latanoprost, and 17.3+/-2.2 mmHg on travoprost (P = 0.001). Individual time points were similar between treatments, except at 6 pm when travoprost provided lower IOP (16.7+/-2.6 vs 17.9+/-2.5 mmHg, P<0.001). Adverse events showed more conjunctival hyperemia with travoprost (n = 15) than latanoprost (n = 6; P = 0.03).

Conclusions: Latanoprost and travoprost both significantly reduce the 24-hour IOP from baseline in exfoliative glaucoma, but travoprost may demonstrate a greater hypotensive efficacy in the late afternoon.

Citing Articles

Adverse events of topical ocular prostaglandin medications for glaucoma treatment: a pharmacovigilance study based on the FAERS database.

Wu S, Huang C, Wang Y, Li X, Zhang S, Chen X Ther Adv Drug Saf. 2024; 15:20420986241285929.

PMID: 39429679 PMC: 11487502. DOI: 10.1177/20420986241285929.


Pseudoexfoliation Glaucoma: Clinical Presentation and Therapeutic Options.

Yuksel N, Yilmaz Tugan B Turk J Ophthalmol. 2023; 53(4):247-256.

PMID: 37602651 PMC: 10442753. DOI: 10.4274/tjo.galenos.2023.76300.


Efficacy and safety of netarsudil/latanoprost fixed-dose combination vs. monotherapy in open-angle glaucoma or ocular hypertension: A systematic review and meta-analysis of randomized controlled trials.

Luo N, Jiang X, Hao M, Fang Z, Wei Y, Zhang W Front Med (Lausanne). 2022; 9:923308.

PMID: 35979215 PMC: 9376331. DOI: 10.3389/fmed.2022.923308.


Comparison of the effectiveness and safety of travoprost and latanoprost for the management of open-angle glaucoma given as an evening dose.

Li J, Wang X, Xu G, Deng R, Wu L, Zhang L Exp Ther Med. 2020; 20(5):24.

PMID: 32934689 PMC: 7472139. DOI: 10.3892/etm.2020.9152.


Sustainability of Intraocular Pressure Reduction of Travoprost Ophthalmic Solution in Subjects with Normal Tension Glaucoma.

Naito T, Okuma S, Nagayama M, Mizoue S, Ozaki M, Namiguchi K Adv Ther. 2016; 33(3):435-46.

PMID: 26861847 PMC: 4833797. DOI: 10.1007/s12325-016-0297-6.